Jacobson Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Jacobson Pharma yıllık ortalama 1.6% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 5.7% annual. Gelirler growing yılda ortalama 2.2% oranında artmaktadır. Jacobson Pharma'in özkaynak karlılığı 10.3% ve net marjı 16.2%'dir.

Anahtar bilgiler

1.6%

Kazanç büyüme oranı

2.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.6%
Gelir büyüme oranı	2.2%
Özkaynak getirisi	10.3%
Net Marj	16.2%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21

Recent updates

There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump

Nov 22

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Aug 21

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03

Gelir ve Gider Dağılımı

Jacobson Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:2633 Gelir, gider ve kazançlar (HKD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	1,563	253	335
30 Jun 24	1,515	220	334
31 Mar 24	1,468	186	332
31 Dec 23	1,811	221	423
30 Sep 23	1,919	217	458
30 Jun 23	1,852	234	443
31 Mar 23	1,268	175	298
31 Dec 22	1,489	207	360
30 Sep 22	1,427	203	347
30 Jun 22	1,511	190	373
31 Mar 22	1,596	178	398
31 Dec 21	1,548	166	399
30 Sep 21	1,501	154	400
30 Jun 21	1,473	164	404
31 Mar 21	1,446	174	408
31 Dec 20	1,478	183	405
30 Sep 20	1,510	191	403
30 Jun 20	1,541	203	402
31 Mar 20	1,571	214	401
30 Sep 19	1,419	273	365
30 Jun 19	1,449	259	353
31 Mar 19	1,478	245	341
31 Dec 18	1,663	235	343
30 Sep 18	1,622	219	335
30 Jun 18	1,585	211	337
31 Mar 18	1,549	202	339
31 Dec 17	1,486	202	321
30 Sep 17	1,424	203	303
30 Jun 17	1,340	191	304
31 Mar 17	1,256	179	304
31 Dec 16	1,188	142	316
30 Sep 16	1,141	142	322
30 Jun 16	1,112	144	307
31 Mar 16	1,084	146	293
31 Dec 15	1,043	145	275
31 Mar 15	948	102	246
31 Mar 14	926	172	266

Kaliteli Kazançlar: 2633 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 2633 'nin mevcut net kar marjları (16.2%) geçen yılın (11.3%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 2633 şirketinin kazancı son 5 yılda yılda 1.6% oranında arttı.

Büyüme Hızlandırma: 2633 'un son bir yıldaki kazanç büyümesi ( 16.8% ) 5 yıllık ortalamasını (yıllık 1.6% ) aşıyor.

Kazançlar vs. Sektör: 2633 geçen yılki kazanç büyümesi ( 16.8% ) Pharmaceuticals sektörünün 9.4% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 2633 'nin Özsermaye Getirisi ( 10.3% ) düşük olarak değerlendiriliyor.

Jacobson Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Jacobson Pharma Corporation Limited to Report First Half, 2025 Results on Nov 21, 2024

Full year 2024 earnings released: EPS: HK$0.11 (vs HK$0.13 in FY 2023)

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

First half 2024 earnings released: EPS: HK$0.053 (vs HK$0.077 in 1H 2023)

Jacobson Pharma Corporation Limited to Report Q2, 2024 Results on Nov 24, 2023

Full year 2023 earnings released: EPS: HK$0.13 (vs HK$0.093 in FY 2022)

Recent updates

Jacobson Pharma Corporation Limited Announces the Interim Dividend for the Six Months Ended 30 September 2024, Payable on 02 April 2025

There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump

Jacobson Pharma Corporation Limited Announces the Interim Dividend for the Six Months Ended 30 September 2024

Europharm Laboratoires Company Limited agreed to acquire 20.10% stake in Li Chung Shing Tong (Holdings) Limited from Jacobson Pharma Corporation Limited (SEHK:2633) for HKD 46.2 million.

Jacobson Pharma Corporation Limited to Report First Half, 2025 Results on Nov 21, 2024

Jacobson Pharma Corporation Limited Approves Final Cash Dividend for the Year Ended 31 March 2024

Upcoming dividend of HK$0.03 per share

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 28, 2024

Full year 2024 earnings released: EPS: HK$0.11 (vs HK$0.13 in FY 2023)

Jacobson Pharma Corporation Limited has completed a Follow-on Equity Offering in the amount of HKD 39.6 million.

New minor risk - Shareholder dilution

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Upcoming dividend of HK$0.025 per share at 7.7% yield

First half 2024 earnings released: EPS: HK$0.053 (vs HK$0.077 in 1H 2023)

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

New minor risk - Earnings quality

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended September 30, 2023, Payable on 10 January 2024

Jacobson Pharma Corporation Limited to Report Q2, 2024 Results on Nov 24, 2023

New minor risk - Share price stability

Now 40% undervalued after recent price drop

Upcoming dividend of HK$0.024 per share at 5.3% yield

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 01, 2023

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2023, Payable on 1 September 2023

Full year 2023 earnings released: EPS: HK$0.13 (vs HK$0.093 in FY 2022)

Jacobson Pharma Corporation Limited to Report Fiscal Year 2023 Results on Jun 15, 2023

Upcoming dividend of HK$0.028 per share

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 29 December 2022

First half 2023 earnings released: EPS: HK$0.071 (vs HK$0.042 in 1H 2022)

Less than half of directors are independent

Jacobson Pharma Corporation Limited to Report First Half, 2023 Results on Nov 25, 2022

Upcoming dividend of HK$0.027 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Jacobson Pharma Corporation Limited Approves Final Dividend for the Year Ended 31 March 2022

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma Corporation Limited, Annual General Meeting, Sep 23, 2022

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Chairman recently bought HK$1.6m worth of stock

Full year 2022 earnings released

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2022, Payable on 18 October 2022

Jacobson Pharma Corporation Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Chairman recently bought HK$237k worth of stock

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Chairman recently bought HK$341k worth of stock

Chairman recently bought HK$377k worth of stock

Upcoming dividend of HK$0.012 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

First half 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of HK$0.015 per share

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Full year 2021 earnings released: EPS HK$0.091 (vs HK$0.11 in FY 2020)

The board of Jacobson Pharma Corporation Limited (SEHK:2633) completed the spin off of an unknown stake of Branded healthcare business.

Independent Non-Executive Director recently bought HK$144k worth of stock

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Investor sentiment deteriorated over the past week

New 90-day low: HK$1.07

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Second quarter 2021 earnings released: EPS HK$0.027

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

New 90-day high: HK$1.20

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Second quarter 2021 earnings released: EPS HK$0.027